Neuraxis
Manufacturing · Indiana, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11550 N Meridian St Ste 325, Carmel, Ind...Phone Number
(812) 689-0791Website
www.neuraxis.comRevenue
$5.3 MillionStock Symbol
NRXSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Neuraxis
NeurAxis is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating condition in children. They are headquartered in Carmel, Indiana. Founded in 2011.Explore more
Neuraxis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neuraxis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Neuraxis
Check if Neuraxis has recently received funding, and reach out quickly before it becomes old news!
Click to see if Neuraxis had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Neuraxis recently announced quarterly report
Check out if Neuraxis is spiking on competitors!
Product Launch: Get notified when Neuraxis launches new products
Neuraxis, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Neuraxis has new funding data
Recommended Actions
Find VP level buyers at Neuraxis
Find 3 more new buyers
Compare Similar Companies to Neuraxis
Compare insights from companies similar to Neuraxis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Neuraxis
$5.3M
11-50
Public
$9.6M
2011
AM
Adrian MirandaSenior VP, Science & Chief Medical Officer, Technology
Company Profile Activity
Activity Insights
Neuraxis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neuraxis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neuraxis.
Neuraxis financials insights
Gather financial insights about Neuraxis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Stock Offering
$6.6M
Stock Offering
$3M
Neuraxis Tech Stack
A closer look at the technologies used by Neuraxis
Most Recent Scoops
Earnings
Neuraxis has reported that revenue growth of 116% and 98% for the three and six months ended June 30, 2026, respectively, continues to outpace operating expense growth by two to four times compared to the same periods in 2025.
Earnings, Finance
Earnings
Neuraxis has reported year-to-date revenue of $3.6 million for 2026, up 98% compared to $1.8 million in 2025, with an IB-Stim average selling price of $1,003, up 30% from $772 in 2025, a year-to-date internal prior authorization approval rate of 31% versus 12% in 2025, 88 ordering accounts year-to-date versus 76 at the same point in 2025, and year-to-date revenue per ordering account of $40,000 versus $24,000 in 2025, up 68%.
Earnings, Finance
Earnings
Neuraxis has reported a gross margin of 85.9% for Q2 2026, an increase of 230 basis points compared to 83.6% in Q2 2025, and a gross margin of 86.1% for the six months ended June 30, 2026, up 210 basis points from 84% for the same period in 2025, driven by the adoption of the Category I CPT code and increased payer coverage shifting unit growth toward full reimbursement payers.
Earnings, Finance
Earnings
Neuraxis has reported selling expenses of $862,000 for Q2 2026, a 61% increase compared to $534,000 in Q2 2025, and selling expenses of $1.7 million for the six months ended June 30, 2026, a 63% increase compared to $1 million for the same period in 2025, driven by higher sales commissions, additional sales and marketing personnel, recruiting costs, and increased travel expenses related to IB-Stim Category I CPT code adoption and expanded payer coverage.
Earnings, Sales, Finance
Earnings
Accounting, Financial Reporting, Finance
Neuraxis News & Media
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
Conference call will be held today, Tuesday, August 11 at 9:00 am ET Conference call will be held today, Tuesday, August 11 at 9:00 am ETNeurAxis Expands Payer Coverage with New Policies
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-ANeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am E
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neuraxis
Sign Up For FreeTo access detailed company insights
NeurAxis is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating condition in children. They are headquartered in Carmel, Indiana. Founded in 2011.... Read More
